These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Multicenter Phase II Study: Bendamustine plus Bortezomib plus Dexamethasone in the treatment of stage II/III relapsed or refractory multiple myeloma
|Lenalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failure